Top Fertility Supplements Companies

Fertility Supplements Market size was valued at USD 2.1 Billion in 2023 and is poised to grow from USD 2.27 Billion in 2024 to USD 4.19 Billion by 2032, growing at a CAGR of 8% during the forecast period (2025-2032).

The global fertility supplements market is highly competitive in nature with the presence of various key players. The market is fragmented due to the presence of numerous local and international players, and the high degree of competition is leading to continuous innovation, development, and launching of new products. The competitive landscape of the global fertility supplements market is expected to remain intense, with companies focusing on product innovation, strategic partnerships, and mergers and acquisitions to gain a competitive advantage. 'TTK HealthCare (India)', 'Fairhaven Health LLC (U.S.)', 'Zenith Nutritions (India)', 'INVO Bioscience (U.S.)', 'Vitabiotics Ltd (U.K.)', 'Bionova Lifesciences (India)', 'Exeltis USA Inc. (U.S.)', 'Fujifilm Irvine Scientific, Inc. (U.S.)', 'Coast Science (U.S.)', 'Orthomol (Germany)', 'Theralogix LLC (U.S.)', 'Mira (U.S.)', 'Proxeed Plus (U.S.)', 'Fertility Nutraceuticals LLC (U.S.)', 'Fertility Focus Limited (U.K.)', 'DCC plc (Ireland)', 'Purelife Bioscience Co. Ltd. (Taiwan)', 'Fertility Smart (Australia)', 'Concepta Diagnostics (U.K.)', 'TTK Prestige Ltd (India)'

Fertility Supplements Market Drivers 

Increasing demand for natural and organic supplements: Consumers are increasingly opting for natural and organic fertility supplements as they are perceived to be safer and have fewer side effects. These supplements are made from natural ingredients such as herbs, vitamins, and minerals, and do not contain any synthetic substances. For instance, In folic, a natural supplement made from myo-inositol and folic acid, has gained popularity in the market due to its natural composition and effectiveness in promoting fertility.

North America held the largest share in the global fertility supplements market. Data from the Centers for Disease Control and Prevention (CDC) update indicated that 14.1% of women aged 15 to 49 in the U.S. had impaired fertility, while 15.1% of married women aged 15 to 49 had impaired fertility. In addition, 7% of married women were found to be infertile, which has increased the demand for fertility products in the region. Furthermore, the market in Canada is expected to grow rapidly due to initiatives by the government and nonprofit organizations such as Fertility Matters Canada to raise awareness about fertility medication and treatment, as well as the rising rates of obesity and sexually transmitted infections.